NCT06084962

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: He Huang · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma

Detailed description

In this study, 60 patients with relapsed refractory multiple myeloma were proposed to undergo DeepTag-GPRC5D CAR-T cell therapy. Under the premise that its safety has been clarified in previous studies, further observation and evaluation of the effectiveness of DeepTag-GPRC5D CAR-T cell therapy for relapsed refractory multiple myeloma; At the same time, on the basis of expanding the sample size, more safety data on DeepTag-GPRC5D CAR-T cell treatment for relapsed refractory multiple myeloma were accumulated, including rare and delayed complications.

Conditions

• Relapse/Refractory Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	DeepTag-GPRC5D Targeted CAR T-cells	Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion

Timeline

• Start date: 2023-10-20
• Primary completion: 2026-10-20
• Completion: 2026-10-20
• First posted: 2023-10-16
• Last updated: 2023-10-16

Locations

1 site across 1 country: China